BICYCLE THERAPEUTICS PLC

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing synthetic bicyclic peptides, termed Bicycle molecules, to treat diseases with significant unmet medical need. The company utilizes a proprietary phage display screening platform to discover and engineer therapeutics across multiple drug modalities, including drug conjugates, radioconjugates, imaging agents, and immune cell agonists. Its primary internal pipeline centers on oncology, led by product candidates such as nuzefatide pevedotin and the radiopharmaceutical BT1702. In addition to internal discovery, the company collaborates with external biopharmaceutical partners to develop therapies across various disease indications, including cardiometabolic, central nervous system, and neuromuscular conditions.

The company operates internationally, maintaining an intellectual property portfolio that spans ten distinct territories: the United Kingdom, the European Union, the United States, Japan, Hong Kong, Australia, China, Israel, Switzerland, and Norway. Research activities and clinical collaborations are conducted in partnership with leading global institutions, such as the German Cancer Research Center and Universitätsmedizin Essen. The provided text does not identify the location of the company's headquarters.

Summary of the business section of Bicycle Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 288 full-time or part-time employees, including 108 with M.D.”